Has the time come for metronomics in low-income and middle-income countries?

The Lancet Oncology

Volumn 14, Issue 6, 2013, Pages

  André, Nicolas ^a,b,c   Banavali, Shripad ^b,d   Snihur, Yuliya ^b,e   Pasquier, Eddy ^b,f  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^b Metronomics Global Health Initiative   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d TATA MEMORIAL HOSPITAL   (India)

^e IESE BUSINESS SCHOOL   (Spain)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CELECOXIB; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; FULVESTRANT; GEMCITABINE; LOMUSTINE; METHOTREXATE; NAVELBINE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RETINOIC ACID; TAMOXIFEN; THALIDOMIDE; TIOGUANINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; DRUG REPOSITIONING; DRUG TREATMENT FAILURE; EWING SARCOMA; HEALTH CARE ACCESS; HUMAN; LIVER CELL CARCINOMA; LOWEST INCOME GROUP; LYMPHOMA; METRONOMIC CHEMOTHERAPY; MIDDLE INCOME GROUP; MOUTH CANCER; MULTIPLE CYCLE TREATMENT; NEPHROBLASTOMA; NONHODGKIN LYMPHOMA; NOTE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; RHABDOMYOSARCOMA; RURAL AREA; SOCIAL STATUS; SOFT TISSUE SARCOMA; SOLID TUMOR; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84876954809     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70056-1     Document Type: Note

References (76)

1. Swaminathan R, Lucas E, Sankaranarayanan R Cancer survival in Africa, Asia, the Caribbean and Central America: database and attributes. IARC Sci Publ 2011, 162:23-31.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
3. Varmus H, Trimble EL Integrating cancer control into global health. Sci Transl Med 2011, 3:101cm28.
4. Rosenbaum L, Lamas D Facing a " slow-motion disaster" -the UN meeting on noncommunicable diseases. N Engl J Med 2011, 365:2345-2348.
5. Adams C, Torode J, Henshall S, Cazap E, Ryel AL, Grey N The World Cancer Declaration: from resolution to action. Lancet Oncol 2011, 12:1091-1092.
6. Patel JD, Galsky MD, Chagpar AB, Pyle D, Loehrer PJ Role of American Society of Clinical Oncology in low- and middle-income countries. J Clin Oncol 2011, 29:3097-3102.
7. Moving cancer up the global health agenda. Lancet 2010, 375:2051. The Lancet.
8. Magrath I Cancer in low and middle income countries. Health G20: a briefing on health issues for G20 leaders 2010, 58-68. Probrook, Sutton, UK. M. Carballo (Ed.).
9. Dikshit R, Gupta PC, Ramasundarahettige C, et al. Cancer mortality in India: a nationally representative survey. Lancet 2012, 379:1807-1816.
10. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011, 12:933-980.
11. Philipson T, Eber M, Lakdawalla DN, Corral M, Conti R, Goldman DP An analysis of whether higher health care spending in the United States versus Europe is " worth it" in the case of cancer. Health Aff (Millwood) 2012, 31:667-675.
12. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011, 103:117-128.
13. Bach PB, Saltz LB, Wittes RE In cancer care, cost matters (accessed Dec 10, 2012). http://www.nytimes.com/2012/10/15/opinion/a-hospital-says-no-to-an-11000-a-month-cancer-drug.html.
14. Model list of essential medicines. 17th model list 2011 WHO, (accessed Dec 10, 2012). http://www.who.int/medicines/publications/essentialmedicines/en/index.html.
15. Kerr DJ, Midgley R Can we treat cancer for a dollar a day? Guidelines for low income countries. N Engl J Med 2010, 363:801-803.
16. André N, Padovani L, Pasquier E Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?. Future Oncol 2011, 7:385-394.
17. André N, Pasquier E, Kamen B Can targeted therapy be successful without metronomic scheduling?. Curr Top Med Chem 2012, 12:1639-1642.
18. Pasquier E, Kavallaris M, André N Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010, 7:455-465.
19. Klement GL, Kamen BA Nontoxic, fiscally responsible, future of oncology: could it be beginning in the third world?. J Pediatr Hematol Oncol 2011, 33:1-3.
20. Kerbel RS, Kamen BA The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004, 4:23-36.
21. Ashburn TT, Thor KB Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004, 3:673-683.
22. Khan Z, Khan N, Tiwari RP, Sah NK, Prasad GB, Bisen PS Biology of Cox-2: an application in cancer therapeutics. Curr Drug Targets 2011, 12:1082-1093.
23. Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999, 5:1418-1423.
24. Tan J, Cang S, Ma Y, Petrillo RL, Liu D Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010, 3:5.
25. Weller M, Gorlia T, Cairncross JG, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 2011, 77:1156-1164.
26. Osmak M Statins and cancer: current and future prospects. Cancer Lett 2012, 324:1-12.
27. Barrière G, Tartary M, Rigaud M Metformin: a rising star to fight the epithelial mesenchymal transition in oncology. Anticancer Agents Med Chem 2013, 13:333-340.
28. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007, 67:10804-10812.
29. Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 2010, 17:388-399.
30. Saulnier Sholler GL, Brard L, Straub JA, et al. Nifurtimox induces apoptosis of neuroblastoma cells in vitro and in vivo. J Pediatr Hematol Oncol 2009, 31:187-193.
31. Pasquier E, Ciccolini J, Carre M, et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget 2011, 2:797-809.
32. Powe DG, Entschladen F Targeted therapies: using beta-blockers to inhibit breast cancer progression. Nat Rev Clin Oncol 2011, 8:511-512.
33. Lamkin DM, Sloan EK, Patel AJ, et al. Chronic stress enhances progression of acute lymphoblastic leukemia via β-adrenergic signaling. Brain Behav Immun 2012, 26:635-641.
34. Kellie SJ, Howard SC Global child health priorities: what role for paediatric oncologists?. Eur J Cancer 2008, 44:2388-2396.
35. Gebbia V, Bellavia G, Ferraù F, Valerio MR Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents. Expert Opin Drug Saf 2012, 11(suppl 1):S49-S59.
36. Ruddy K, Mayer E, Partridge A Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009, 59:56-66.
37. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002, 13:73-80.
38. Aurilio G, Munzone E, Botteri E, et al. Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report. Breast J 2012, 18:470-474.
39. Fedele P, Marino A, Orlando L, et al. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. Eur J Cancer 2012, 48:24-29.
40. Yoshimoto M, Takao S, Hirata M, et al. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer. Cancer Chemother Pharmacol 2012, 70:331-338.
41. Ang SF, Tan SH, Toh HC, et al. Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma. Am J Clin Oncol 2012, 35:222-227.
42. Gebbia V, Serretta V, Borsellino N, Valerio MR Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel. Urology 2011, 78:1125-1130. for the GSTU Foundation.
43. Buckstein R, Kerbel RS, Shaked Y, et al. High-dose celecoxib and metronomic «low-dose» cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 2006, 12:5190-5198.
44. Coleman M, Martin P, Ruan J, et al. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer 2008, 112:2228-2232.
45. Mir O, Domont J, Cioffi A, et al. Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. Eur J Cancer 2011, 47:515-519.
46. Penel N, Adenis A, Bocci G Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?. Crit Rev Oncol Hematol 2012, 82:40-50.
47. Banavali SD, Nair C, Muckaden M, Laskar S, Advani S Biologic response modifier (BRM) based therapy in children with residual or recurrent Ewing's sarcoma family tumors (ESF) or rhabdomyosarcoma (RMS). SIOP XXXIV Meeting - Abstracts (P-035). Med Ped Oncol 2002, 39:287. (abstr).
48. Banavali S, Biswas G, Nair CN, Kurkure PA, Saikia TK, Parikh PM PRET: an effective oral protocol for out-patient therapy in patients with acute myeloid leukemia. Pediatr Blood Cancer 2004, 43:355. (O 109).
49. Banavali S, Goyal L, Nair R, et al. A novel, efficacious approach to patients with APL using differentiating agent and metronomic chemotherapy. Blood 2005, 106:900. (abstr).
50. Fousseyni T, Diawara M, Pasquier E, André N Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01. J Pediatr Hematol Oncol 2011, 33:31-34.
51. Banavali S, Singh R, Prasad M, et al. Is there a role for a novel maintenance therapy in pediatric patients with AML?. Pediatr Blood Cancer 2011, 57:770.
52. Pai P, Vaidya A, Prabhash K, Banavali S Oral metronomic chemotherapy in advanced oral squamous cell cancers: a matched pair analysis. Oral Oncol 2011, 47:S79. (P17).
53. Mwanda WO, Orem J, Fu P, et al. Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa. J Clin Oncol 2009, 27:3480-3488.
54. Patil V, Noronha V, D'cruz AK, Banavali SD, Prabhash K Metronomic chemotherapy in advanced oral cancers. J Cancer Res Ther 2012, 8(suppl 1):S106-S110.
55. Bhattacharyya GS, Basu S, Agarwal V, et al. Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple-negative. Eur J Cancer 2009, 7(3 suppl):18.
56. Rapkin L, Qayed M, Brill P, et al. Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. Pediatr Blood Cancer 2012, 59:854-858.
57. Pappo AS, Patel SR, Crowley J, et al. LH.R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research Through Collaboration study. J ClinOncol 2011, 29:4541-4547.
58. Dinshaw KA, Pimple SA, Dikshit RP, Ganesh B Model district cancer control programme. Cancer awareness, prevention and control: strategies for South Asia-A UICC Handbook 2006, 198-209. UICC Publications, Geneva. K.A. Dinshaw (Ed.).
59. Amit R, Zott C Value creation in e-business. Strat Mgmt J 2001, 22:493-520.
60. Amit R, Zott C Creating value through business model innovation. Sloan Mgmt Review 2012, 53:41-49.
61. Teece DJ Business models, business strategy and innovation. Long Range Planning 2010, 43:172-194.
62. Seelos C, Mair J Profitable business models and market creation in the context of deep poverty: a strategic view. Acad Manage Perspect 2007, 21:49-63.
63. Sanchez P, Ricart JE Business model innovation and sources of value creation in low-income markets. European Mgmt Review 2010, 7:138-154.
64. Yunus M, Moingeon B, Lehmann-Ortega L Building social business models: lessons from the Grameen experience. Long Range Planning 2010, 43:308-325.
65. Kaplan RS, Porter ME How to solve the cost crisis in health care. Harvard Bus Rev 2011, 89:46-64.
66. Haupt S, Kramer A Bringing medicine to low-income markets: a guide to creating inclusive business models for pharmaceutical companies 2012, Deutsche Gesellschaft fur Internationale Zusammenarbeit, GmbH, Berlin, Germany.
67. Hwang J, Christensen CM Disruptive innovation in health care delivery: a framework for business model innovation. Health Affairs 2008, 27:1329-1335.
68. Velayudhan SK, Sundaram MR, Thulasiraj RD Aravind eye care system: providing total eye care to the rural population. Richard Ivey School of Business Foundation Case Study 2011, University of Western Ontario, Toronto, 8B11A028.
69. Bhandari A, Dratler S, Raube K, Thulasiraj RD 2008. Specialty care systems: a pioneering vision for global health. Health Affairs 2008, 27:964-976.
70. Israels T, Chagaluka G, Pidini D, et al. The efficacy and toxicity of SIOP preoperative chemotherapy in Malawian children with a Wilms tumour. Pediatr Blood Cancer 2012, 59:636-641.
71. Briasoulis E, Pappas P, Puozzo C, et al. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res 2009, 15:6454-6461.
72. Nasti G, Errante D, Talamini R, et al. Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a phase II study. J Clin Oncol 2000, 18:1550-1557.
73. Huang ME, Ye YC, Wang ZY Treatment of 4 APL patients with all-trans retinoic acid. Chin J Intern Med 1987, 26:322-330.
74. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia, I: clinical results. Blood 1990, 76:1704-1709.
75. Wang ZY Ham-Wasserman Lecture. Treatment of acute leukemia by inducing differentiation and apoptosis. Hematol Am Soc Hematol Educ Program 2003, 1-13.
76. Palfrey S Daring to practice low-cost medicine in a high-tech era. N Engl J Med 2011, 364:e21.